Drug intelligence / Profile preview

tininurad

Development stage: Unknown
Lead developer: Tianjin Institute of Pharmaceutical Research
Modality: Small Molecules
Administration: Oral

Overview

Tininurad is a small molecule selective urate transporter 1 (URAT1) inhibitor developed by the Tianjin Institute of Pharmaceutical Research for the treatment of hyperuricemia and gout. By inhibiting URAT1, a transporter protein located in the proximal tubule of the kidney responsible for the majority of uric acid reabsorption, tininurad increases the renal excretion of uric acid, thereby lowering serum uric acid levels. It is currently being evaluated in Phase 2 clinical trials to assess its efficacy and safety in patients with gout and hyperuricemia.

Targets

URAT1 (Uric Acid Transporter 1)

Beyond the preview

Go deeper on tininurad.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on tininurad.

Explore the full profile